Key takeaways
- ~3,500 US PNH patients on complement-inhibitor therapy — ~55% ravulizumab, ~25% eculizumab, ~10% iptacopan
- 800–1,200 US patients with EVH-driven residual anaemia despite anti-C5 therapy — the pre-launch target cohort
- 82% Iptacopan Hgb responder rate in EVH-dominant patients (APPLY-PNH) — the oral efficacy bar a new entrant must clear
- ~$550K/yr Iptacopan WAC — the pricing ceiling for a second oral PNH agent absent head-to-head superiority data
The binding constraint: beat iptacopan's oral bar in the EVH-anaemia cohort that anti-C5 blockade cannot resolve — inside a pricing ceiling iptacopan already set.
Ravulizumab and eculizumab together cover roughly 80% of the ~3,500 US PNH patients on complement-inhibitor therapy, with switching inertia high once patients are haemolysis-controlled and clinically stable on IV anti-C5. The clinical gap that keeps the market open: 25-35% of C5-inhibitor patients, an estimated 800-1,200 US patients, have persistent anaemia from extravascular haemolysis (EVH), a mechanism proximal to C5 that anti-C5 blockade does not address. Iptacopan (Fabhalta), approved November 2023, already claimed the first-mover oral and proximal-complement slot against this exact cohort, reporting an 82% haemoglobin responder rate and building roughly 10% US share within six months of launch.
For a pre-launch entrant, iptacopan's evidence and pricing now define the bar, not the anti-C5 incumbents. The addressable population is narrower than 'all PNH': the EVH-dominant, transfusion-requiring segment (an estimated 600-900 US patients transfusing at least once a year despite C5 inhibition) is the FDA-recognised, commercially defensible target that iptacopan's own trial data did not fully close out. A second consideration is diagnosis: 500-700 new US PNH patients are identified annually, with a 1-2 year diagnostic delay and an estimated 200-400 patients per year going undertreated at non-PNH-centre hospitals — an addressable but currently under-served volume.
Payer posture is being written in real time rather than already fixed. Major PBMs (UHC, Cigna, CVS/Caremark) are actively forming prior-authorisation criteria for oral PNH agents around FLAER-confirmed clone size, LDH thresholds, and haematology specialist sign-off — with iptacopan's ~$550,000/year WAC setting the price anchor a new entrant will be measured against. Pre-launch priorities follow directly from this: build a prospective EVH-identification registry across the 15-20 US PNH centres now, engage the roughly 50 national/regional PNH KOLs who control 80% of volume, and decide the access architecture, price at parity, below, or only at a premium backed by head-to-head superiority data, before the PBM formulary review windows close.
Current PNH standard of care — US, 2024
| Drug (Brand / INN) | Mechanism | US Share | WAC | Addresses EVH/Residual Anaemia? | Payer PA Posture |
|---|---|---|---|---|---|
| Ultomiris / Soliris (ravulizumab / eculizumab) | Anti-C5 mAb IV — incumbent SoC (q8w / q2w) | ~80% combined (~55% + ~25%) | Ultomiris ~$575,000/yr WAC (Soliris WAC not detailed in source) | No — EVH/residual anaemia persists despite haemolysis control | Established Part B incumbent; high switching inertia in stable patients |
| Fabhalta (iptacopan) | Factor B inhibitor — oral, first-mover proximal complement | ~10% (first 6 months post-launch) | ~$550,000/yr WAC | Yes — 82% Hgb responder rate in EVH-dominant patients (APPLY-PNH) | PA criteria forming (FLAER + LDH + specialist); sets the pricing ceiling for a new entrant |
Sources: IQVIA PNH market data 2024; APLASTIC ANEMIA and MDS International Foundation PNH registry; APPLY-PNH EVH sub-analysis (Peffault de Latour R, NEJM 2022); UHC specialty drug formulary Q2 2024; ICER PNH Evidence Report (2024).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- What must a new PNH agent prove to overcome switching inertia from stable anti-C5 therapy and clear the oral efficacy bar iptacopan has already set? • EVH/residual-anaemia response benchmarks vs APPLY-PNH • physician switch triggers (Hgb threshold, transfusion history) • positioning logic against a first-mover oral agent
- How large is the US EVH/residual-anaemia PNH cohort, and how should it be identified and tracked ahead of approval? • Cohort sizing (800-1,200 patients) by mechanism • registry and Hgb-tracking design across the 15-20 US PNH centres • diagnostic-delay and undertreated-population estimate
- What PA criteria and value benchmarks are payers setting for oral PNH agents right now, and what access architecture should a pre-launch entrant build? • FLAER/LDH-based PA criteria forming at UHC, Cigna, CVS/Caremark • ICER-style cost-effectiveness benchmark analogous to iptacopan • WAC positioning options (parity, discount, premium)
What's inside
-
1 · The Binding Constraint 2 pp
- The EVH/residual-anaemia gap as the single variable deciding launch success
- Pressure-tested against iptacopan's existing oral evidence and price anchor
-
2 · Standard-of-Care Landscape & Entrenchment 5 pp
- Anti-C5 IV incumbency (ravulizumab, eculizumab) and switching inertia
- Iptacopan's first-mover oral/proximal-complement position
- Where the incumbent class is clinically exposed (EVH, transfusion dependency)
-
3 · Target Population & Unmet Need 5 pp
- EVH-dominant, transfusion-requiring cohort sizing (800-1,200 patients)
- Diagnosis-to-treatment gap: 500-700 new diagnoses/year, 1-2 year delay
- Registry and Hgb-tracking infrastructure to build pre-approval
-
4 · Anticipated Payer & Access Posture 5 pp
- PA criteria forming at UHC, Cigna, CVS/Caremark (FLAER, LDH thresholds)
- ICER-style value benchmark analogous to iptacopan's cost/QALY exposure
- WAC positioning options relative to the ~$550K/year iptacopan anchor
-
5 · The Assumption Register 2 pp
- Every population, share, and pricing figure sourced and confidence-rated
- Built to survive an internal challenge meeting
-
6 · KOL & Centre Readiness 3 pp
- The 15-20 US PNH centres and ~50 KOLs managing 80% of volume
- Pre-launch engagement sequencing
- Oral-vs-IV switch triggers by physician and patient
-
7 · Client Alignment Questions 2 pp
- Open decisions on pricing, label scope, and registry investment
- Structured for an advisory board or internal alignment session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers PNH launch-readiness intelligence built for pre-launch commercial, medical affairs, and market access teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your asset, target population, and pre-launch question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and access-architecture assumptions.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment synthesises three independent research angles into one integrated pre-launch view: competitive positioning, target-population epidemiology, and anticipated payer posture. Every figure is drawn from the named primary source in the underlying research base and cross-checked before inclusion; no figure is carried from model memory.
PNH launch-readiness sources: IQVIA PNH market data 2024; APLASTIC ANEMIA and MDS International Foundation PNH registry; Peffault de Latour R et al., NEJM 2022 (APPLY-PNH EVH sub-analysis); Hill A et al., Am J Hematol 2022 (EVH review); Schubert J et al., Blood 2023 (EVH analysis); FDA Guidance for PNH clinical trial endpoints; UHC specialty drug formulary Q2 2024; Cigna PA criteria PNH 2024; CVS/Caremark PNH tier review 2024; ICER PNH Evidence Report (2024); Leeds/US PNH centre referral pattern analysis.
- Drug approval dates and mechanism claims verified against FDA approval records referenced in the source research base
- Clinical trial results (APPLY-PNH, HERCULES, TRIUMPH) verified against the named primary publications in the source research base
- Payer PA-criteria language cross-checked against named payer formulary/policy sources (UHC, Cigna, CVS/Caremark) in the source research base
- Anticipated payer posture is explicitly flagged as anticipated, not confirmed policy, and separated from verified clinical/regulatory facts
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned Launch Readiness assessment includes a 24-30 page PDF covering the binding constraint, SoC entrenchment, target-population sizing, and anticipated payer posture; an editable Excel population-sizing and access-scenario model; and a 12-15 slide PowerPoint readout. A 45-minute analyst call is included with delivery.
Sources How are figures verified for a pre-launch assessment?
Every figure is cited to a live source at the point of writing and cross-checked in an independent audit pass: prescription data, patient-registry reporting, and the published extravascular-haemolysis sub-analyses. Anticipated payer posture is explicitly distinguished from confirmed policy throughout.
Customisation Can I tailor scope to my specific asset or target population?
Yes. The intake form captures your asset's mechanism, target patient segment, and the specific pre-launch question you need answered — a scoping call confirms comparators and access-architecture assumptions before research begins.